LONDON–(BUSINESS WIRE)–#Biotechnology–The global hairy cell leukemia therapeutics market is expected to post a CAGR of over 6% during the period 2019-2023, according to the latest market research report by Technavio.
Hairy cell leukemia is a slow-growing, rare type of chronic cell leukemia. It is caused mainly due to the excess production of white blood cells by the bone marrow stem cells. Many research studies have proven that exposure to hazardous substances develops very high chances of developing hairy cell leukemia. Exposure to hazardous substances can happen due to various types of occupations such as farming, working in manufacturing plants that deal with hazardous chemicals and fumes; and working in coal mines. For instance, from manufacturers to farmers, everyone is exposed to chemical fertilizers, pesticides, and insecticides regularly. Thus, the increasing exposure to such hazardous substances adds to the multifactorial etiology of hairy cell, which is expected to drive the growth of the market during the forecast period.
As per Technavio, the advent of novel therapies will have a positive impact on the market and contribute to its growth significantly over the forecast period. This global hairy cell leukemia therapeutics market 2019-2023 research report also analyzes other important trends and market drivers that will affect market growth over 2019-2023.
Global Hairy Cell Leukemia Therapeutics Market: Advent of Novel Therapies
Currently, the global hairy cell leukemia therapeutics market has been witnessing some advances in research, which have led to the launch of a few novel therapies. The strong prevalence of various types of blood cancer at the global level has necessitated the development of advanced therapies such as kinase inhibitors and gene therapies to treat such conditions. Targeted therapies such as immune checkpoint inhibitors, tyrosine kinase inhibitors, and PD-1 inhibitors are highly effective in the treatment of lymphoma. After the success in other types of blood cancer, these therapies are now being considered for the treatment of hairy cell leukemia. Thus, the advent of novel therapies is likely to offset the challenges posed by the adverse effects of chemotherapy drugs, which will contribute to the growth of the market during the forecast period.
“Apart from the advent of novel therapies, research grants for blood cancer and the increase in special drug designations are some other major factors that are expected to boost market growth during the forecast period,” says a senior analyst at Technavio.
Global Hairy Cell Leukemia Therapeutics Market: Segmentation Analysis
This market research report segments the global hairy cell leukemia therapeutics market by product (chemotherapy and targeted therapy) and geographical regions (North America, Europe, Asia, and ROW).
The North American region led the market in 2018, followed by Europe, Asia, and ROW, respectively. However, during the forecast period, the Asian region is expected to register the highest incremental growth due to the large geriatric population in the region.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market size and forecast
Five Forces Analysis
- Regional comparison
- Key leading countries
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Competitive scenario
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at [email protected].
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200